Verily Raises $300 Million and Becomes Independent from Alphabet to Advance AI‑Driven Precision Health

Verily, the precision health AI company that originated as one of Alphabet's earliest Google X moonshot projects, has raised $300 million in a new investment round and simultaneously announced a major corporate restructuring that transitions it into a fully independent company. The round was led by Series X Capital and announced on March 19, 2026, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors.

The most significant structural change accompanying the raise: Alphabet will become a significant minority investor in Verily but will no longer hold a controlling stake, marking the end of over a decade of Alphabet ownership. Verily has also transitioned its legal structure from an LLC to a corporation, officially adopting the name Verily Health Inc. The company, which originated in 2015 and relocated its headquarters from San Francisco to Dallas, Texas in 2024, now operates as a standalone entity for the first time in its history.

What Verily Actually Does

Verily is a data platform and technology company purpose‑built to power AI‑enabled precision health solutions that accelerate research and improve care. Its technology sits at the intersection of three disciplines: technology, data science, and healthcare. The company transforms multimodal health data into insights, predictive models, and actionable intelligence that health systems and life sciences organizations can deploy in clinical and research workflows.

Its primary product offerings include:

• Verily Pre Platform: The company's core research infrastructure tool, designed to help life sciences companies and health systems organize fragmented healthcare records, genomic datasets, and wearable device data so it can be analyzed by AI systems to discover new biomarkers and accelerate clinical trials. The Pre platform already powers the NIH's All of Us Research Program, supporting more than 21,500 researchers worldwide.
• Verily Me: An AI‑driven consumer health companion application that delivers personalized health recommendations from licensed providers based on individual medical history. Violet, the AI companion embedded in Verily Me, provides 24/7 health assistance to users.
• Lightpath: An AI‑native care management program for patients with chronic diseases including diabetes, subsidized through employer and payer partnerships.
• Sightline: A wastewater‑based epidemiology program that uses AI to enable early detection of infectious diseases, supporting nationwide health monitoring infrastructure.

Why Independence from Alphabet Matters

The question of why Alphabet is relinquishing its controlling stake requires context. In enterprise healthcare, vendor neutrality is a commercial necessity. Health systems, hospital networks, and pharmaceutical companies that are potential Verily customers often have complex, competitive, or cautious relationships with Google and Alphabet as corporate entities. A company fully controlled by Google faces structural friction when approaching partners who compete with Google's cloud products, use competing technology stacks, or have data governance concerns about sharing sensitive patient information within an Alphabet subsidiary.

By becoming truly independent, Verily Health Inc. unlocks the ability to:

• Partner freely across the entire technology ecosystem, including with Google competitors
• Pursue contracts with health systems and payers that were previously cautious about Alphabet data governance
• Cross technology fault lines that constrained its commercial expansion as an Alphabet unit
• Establish relationships with institutional investors, including sovereign wealth funds and hospital systems, that bring clinical credibility alongside capital

This strategic shift is already producing visible results. Alongside the funding, Verily announced major commercial partnerships that explicitly cross traditional Big Tech boundaries:

• A collaboration with Samsung to integrate the Galaxy Watch 8 with the Verily Pre platform for biomarker development and real‑world population monitoring in clinical research
• A strategic partnership with Salesforce to integrate the Verily Pre Platform with Salesforce's Agentforce Health, combining precision medical data with enterprise CRM and workflow infrastructure
• A deepened collaboration with UCHealth and the University of Colorado Anschutz, which became investors in this round after establishing a strategic clinical research partnership in late 2025

The Precision Health AI Market Opportunity

Verily is targeting one of the most persistent and high‑value problems in modern medicine: the fragmentation and inaccessibility of clinical data. Health systems globally are generating extraordinary volumes of patient data, including electronic health records, genomic sequences, imaging studies, wearable sensor streams, and lab results, but most of this data sits in siloed, incompatible systems that cannot be analyzed at scale or used to drive personalized care decisions.

The Verily Pre platform is designed to be the data harmonization and AI deployment layer that bridges this gap. By organizing multimodal health data into AI‑ready formats and deploying predictive models into clinical workflows, Verily enables health systems to move from retrospective data review to prospective, personalized care delivery.

The $300 million will specifically be deployed to:

• Expand the Verily Pre platform's data harmonization capabilities and Workbench tools
• Scale the Sightline infectious disease monitoring program nationally
• Grow the Lightpath chronic disease management program to reach more patients
• Launch new AI agents for clinical research and care management workflows
• Drive new commercial partnerships globally across life sciences and health system customers

Investor Perspectives

The lead investor's structure is itself significant. Series X Capital was established in collaboration with Google's X, The Moonshot Factory, specifically to scale the most promising moonshot technologies into commercially disciplined, standalone enterprises. Its involvement as lead investor signals a deliberate strategy to take Verily through the "last mile of incubation" into a financially self‑sustaining business.

Gideon Yu, Founder and Managing Partner of Series X Capital, stated: "Series X Capital was established in collaboration with Google's X, The Moonshot Factory to scale moonshot technologies into consequential, world‑changing companies. We are extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health."

Ruth Porat, President and Chief Investment Officer of Alphabet and Google, noted: "Bringing in new investors, alongside Alphabet's ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform."

Key Facts at a Glance

• Company: Verily Health Inc. (formerly Verily Life Sciences, formerly a Google X moonshot)
• Round size: $300 million
• Lead investor: Series X Capital
• Co‑investors: Alphabet (significant minority), UCHealth, University of Colorado Anschutz, others
• Announced: March 19, 2026
• Headquarters: Dallas, Texas (relocated from San Francisco in 2024)
• Corporate change: Transitioned from LLC to corporation; Alphabet relinquishes controlling stake
• Key platforms: Verily Pre, Verily Me, Lightpath, Sightline
• Notable users: NIH All of Us Research Program (21,500+ researchers)
• New partnerships: Samsung Galaxy Watch, Salesforce Agentforce Health

Official Sources: Verily